Dynavax Technologies (NASDAQ:DVAX) Shares Down 2.9%

Dynavax Technologies Co. (NASDAQ:DVAX - Get Free Report) shares dropped 2.9% during mid-day trading on Tuesday . The stock traded as low as $10.78 and last traded at $10.79. Approximately 188,911 shares were traded during trading, a decline of 91% from the average daily volume of 2,100,472 shares. The stock had previously closed at $11.11.

Analyst Ratings Changes

Several equities research analysts recently weighed in on DVAX shares. HC Wainwright reaffirmed a "buy" rating and issued a $29.00 price objective on shares of Dynavax Technologies in a report on Wednesday, August 7th. StockNews.com cut shares of Dynavax Technologies from a "buy" rating to a "hold" rating in a research report on Tuesday, May 28th. Finally, The Goldman Sachs Group cut their price target on shares of Dynavax Technologies from $20.00 to $15.00 and set a "neutral" rating for the company in a report on Thursday, August 8th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, Dynavax Technologies has an average rating of "Moderate Buy" and a consensus price target of $23.67.

Dynavax Technologies Trading Down 2.2 %

The company has a debt-to-equity ratio of 0.35, a quick ratio of 13.18 and a current ratio of 14.18. The firm has a market capitalization of $1.42 billion, a P/E ratio of 181.17 and a beta of 1.37. The firm has a 50 day moving average price of $11.06 and a two-hundred day moving average price of $11.44.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share for the quarter, beating analysts' consensus estimates of $0.06 by $0.02. The business had revenue of $73.80 million during the quarter, compared to analyst estimates of $76.92 million. Dynavax Technologies had a return on equity of 2.76% and a net margin of 6.88%. During the same quarter last year, the company posted $0.03 EPS. On average, equities research analysts expect that Dynavax Technologies Co. will post 0.16 EPS for the current fiscal year.

Institutional Trading of Dynavax Technologies

Several institutional investors have recently made changes to their positions in DVAX. Congress Asset Management Co. MA lifted its position in Dynavax Technologies by 0.4% in the 4th quarter. Congress Asset Management Co. MA now owns 227,135 shares of the biopharmaceutical company's stock worth $3,175,000 after buying an additional 799 shares in the last quarter. Diversified Trust Co raised its holdings in shares of Dynavax Technologies by 3.2% during the first quarter. Diversified Trust Co now owns 29,548 shares of the biopharmaceutical company's stock worth $367,000 after acquiring an additional 925 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Dynavax Technologies by 1.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 118,037 shares of the biopharmaceutical company's stock valued at $1,326,000 after purchasing an additional 1,172 shares during the last quarter. SummerHaven Investment Management LLC grew its stake in Dynavax Technologies by 2.4% in the second quarter. SummerHaven Investment Management LLC now owns 54,926 shares of the biopharmaceutical company's stock valued at $617,000 after purchasing an additional 1,303 shares in the last quarter. Finally, Texas Permanent School Fund Corp increased its position in Dynavax Technologies by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 113,128 shares of the biopharmaceutical company's stock worth $1,404,000 after purchasing an additional 1,467 shares during the last quarter. 96.96% of the stock is currently owned by institutional investors and hedge funds.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.